Summary

Germany Legal Cannabis Market Trends

The Germany legal cannabis market size was estimated at USD 2.04 billion in 2024 and is expected to reach USD 9.66 billion by 2033, growing at a CAGR of 18.9% from 2025 to 2033. Factors such as the growing adoption of cannabis for the treatment of chronic diseases, affirmative legal advancements in the country, increasing research activities on its therapeutic use, and growing adoption and introduction of CBD cosmetic products drive market growth. For instance, in September 2023, Cronos Group Inc. launched the medical brand PEACE NATURALS in Germany. In July, the company signed a distribution agreement with Cansativa Group, a distributor of medical cannabis in Germany.

Furthermore, favorable government initiatives and rising demand for CBD-infused products in Germany fuel the market growth. For instance, the general European Union (EU) position has been adopted by Germany, which allows some form of reasonable sale of non-food CBD products as long as they contain no more than 0.2% delta-9 tetrahydrocannabinol (THC). Moreover, Küsten CBD, a German CBD cosmetics company, offers CBD cosmetics, including Cooling gel for accompanying symptoms of muscle tension, osteoarthritis, and bruises; Warming gel for joint pain and back pain; Tattoo/Body Lotion for dry skin prone to acne and neurodermatitis; Body oil/massage oil (Rose Dream) for daily body care, and Facial Fluid (Anti-Aging - Lime) for dry and sensitive skin.

Moreover, rising prevalence of chronic conditions such as s diabetes, cancer, and neurological conditions and growing research activities and clinical trials in Germany propel the market growth. For instance, in October 2023, Avextra, a biopharmaceutical company, moved forward with a double-blind Phase 2 clinical trial for the use of Belcanto in the treatment of cancer patients in palliative care. This medicine received approval from The German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible ethics committees, with the first patient expected to be dosed in December 2023.

Germany Legal Cannabis Market Report Segmentation

This report forecasts revenue growth and provides at country levels an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the Germany legal cannabis market report based on source, derivatives, and end use:

• Source Outlook (Revenue, USD Million, 2021 - 2033)
• .Hemp
o Hemp oil
o Industrial Hemp
• Marijuana
o Flower
o Oil and Tinctures
• Derivatives Outlook (Revenue, USD Million, 2021 - 2033)
• CBD
• THC
• Others
• End Use Type Outlook (Revenue, USD Million, 2021 - 2033)
• Industrial Use
• Medical Use
o Chronic Pain
o Depression and Anxiety
o Arthritis
o Post Traumatic Stress Disorder (PTSD)
o Cancer
o Migraines
o Epilepsy
o Alzheimers's
o Multiple Sclerosis
o AIDS
o Amyotrophic Lateral Sclerosis
o Tourettes
o Diabetes
o Parkinson's
o Glaucoma
o Others
• Recreational Use

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Source outlook
2.2.2. Derivatives outlook
2.2.3. End Use outlook
2.3. Competitive Insights
Chapter 3. Germany Legal Cannabis Market Variables, Trends, and Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Germany Legal Cannabis Market - Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Germany Legal Cannabis: Market Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTLE Analysis
3.4. Current Market Trends in Cannabis Industry
3.5. Regulatory Scenario
3.6. Cannabis Consumption Pattern Analysis
3.7. Guidelines and Requirements for Cannabis Cultivation
3.8. Cannabis Facility Design and Equipment Requirements
3.9. Reimbursement Policies in the Germany
Chapter 4. Germany Legal Cannabis Market: Segment Analysis, By Source, 2021 - 2033 (USD Million)
4.1. Definition and Scope
4.2. Source Market Share Analysis, 2024 & 2033
4.3. Segment Dashboard
4.4. Germany Legal Cannabis Market, by Source, 2021 to 2033
4.5. Marijuana
4.5.1. Marijuana Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.2. Flower
4.5.2.1. Flower Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.3. Oil and Tinctures
4.5.3.1. Oil and Tinctures Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Hemp
4.6.1. Hemp Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.2. Hemp Oil
4.6.2.1. Hemp Oil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6.3. Industrial Hemp
4.6.3.1. Industrial Hemp Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Germany Legal Cannabis Market: Segment Analysis, By Derivative, 2021 - 2033 (USD Million)
5.1. Definition and Scope
5.2. Derivative Market Share Analysis, 2024 & 2033
5.3. Segment Dashboard
5.4. Germany Legal Cannabis Market, by Derivative, 2021 to 2033
5.5. CBD
5.5.1. CBD Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. THC
5.6.1. THC Estimates and Forecasts, 2021 - 2033 (USD Million)
5.7. Others
5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Germany Legal Cannabis Market: Segment Analysis, By End Use, 2021 - 2033 (USD Million)
6.1. Definition and Scope
6.2. End Use Market Share Analysis, 2024 & 2033
6.3. Segment Dashboard
6.4. Germany Legal Cannabis Market, by End Use, 2021 to 2033
6.5. Medical Use
6.5.1. Medical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. Cancer
6.5.2.1. Cancer Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Chronic Pain
6.5.3.1. Chronic Pain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. Depression and Anxiety
6.5.4.1. Depression and Anxiety Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Arthritis
6.5.5.1. Arthritis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Diabetes
6.5.6.1. Diabetes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Glaucoma
6.5.7.1. Glaucoma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Migraines
6.5.8.1. Migraines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Epilepsy
6.5.9.1. Epilepsy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.10. Multiple Sclerosis
6.5.10.1. Multiple Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.11. AIDS
6.5.11.1. AIDS Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.12. Amyotrophic Lateral Sclerosis
6.5.12.1. Amyotrophic Lateral Sclerosis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.13. Alzheimers's
6.5.13.1. Alzheimers's Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.14. Post Traumatic Stress Disorder (PTSD)
6.5.14.1. Post Traumatic Stress Disorder (PTSD) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.15. Parkinson's
6.5.15.1. Parkinson's Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.16. Tourettes
6.5.16.1. Tourettes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.17. Others
6.5.17.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Recreational Use
6.6.1. Recreational Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Industrial Use
6.7.1. Industrial Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Germany Legal Cannabis Market: Competitive Landscape
7.1. Participant’s Categorization
7.2. Company Market Position Analysis, 2024
7.3. Strategy Mapping
7.4. Company Profiles
7.4.1. The Cronos Group
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Service Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Organigram Holding, Inc.
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Service Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Tilray Brands
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Service Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Canopy Growth Corporation
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Service Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. Aurora Cannabis
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Service Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. SynBiotic
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Service Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Cansativa GmbH
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Service Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. DEMECAN
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Service Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Four 20 Pharma
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Service Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. Avextra Pharma GmbH
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Service Benchmarking
7.4.10.4. Strategic Initiatives